Mark L. Hartman, M.D., presented the following report at the 12th International Congress of Endocrinology.

A group of 2,429 patients was followed for 2.3 years. 1,988 patients were treated with injectable human growth hormone (rHGH) replacement. They were compared to 441 similar patients who did not receive HGH. Bias was eliminated to insure that the treated and untreated groups were comparable except for HGH replacement. Adverse events related to tumor growth and malignancy did not differ significantly between those treated and those not treated. Cardiovascular disease caused 36% of deaths in the treated group and 67% of deaths in the group that did not receive HGH. Cancer occurred in 1.6% of the treated group and 2.7% of the untreated group. Statistical analysis did not reveal any significant difference in adverse events between the treated and untreated groups.

Tucker ME. Growth hormone therapy appears safe in long term, 11-1-2004; Family Practice News; Volume 34, Number 21.

Center for Advanced Medicine
4403 Manchester Ave., Suite 107
Encinitas, California 92024
Monday from 9-5 ~ Tuesday, Wednesday, Thursday from 9-6 ~ Friday from 9-2
Phone: (760) 632-9042
Fax: (760)632-0574
www.CamHealthTalk.com
Map and driving directions

Note: "The information contained on this website and in the audio portions is for information purposes only and is not to be used in lieu of your Health Care practitioners medical advice."